Emerging Markets Earnings: Novo Nordisk Sticks To The Plan
This article was originally published in PharmAsia News
Novo Nordisk has a plan in emerging markets and is sticking to it, as senior executives detailed in the third quarter earnings call.
You may also be interested in...
The French pharma scared investors this week with reports that there might be a CEO shake-up and that the long-booming diabetes franchise may be coming under pressure.
Massachusetts U.S. Attorney’s office, which is also investigating firm’s marketing, now subpoenas Novo Nordisk for documents relating to potential issues at its plant in Kalundborg, Denmark.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.